Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...
Pieris Pharmaceuticals, Inc. is a, clinical-sta...
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics, Inc. is a clinical-stage b...
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
Global Pharma Labs, Inc. is a pharmaceutical company. The San Leandro, California...
Global Pharma Labs, Inc. is a pharmaceutical co...
At Bellerophon Therapeutics, we aim to transform the lives of people suffering fro...
At Bellerophon Therapeutics, we aim to transfor...
Join the National Investor Network and get the latest information with your interests in mind.